(IN BRIEF) Researchers at The Institute of Cancer Research, London, working with Merck KGaA, have developed the first potent small-molecule inhibitors of DHX8, an enzyme involved in pre-mRNA splicing. The compounds are described as “pathfinder molecules” rather than drug candidates, … Read the full press release
Posted in Business, Germany, Healthcare, Investment, Pharma & Biotech, Science, Technology, United Kingdom
Tagged biochemical tests, cancer biology, cancer diversity, Cancer Drug Discovery, cancer evolution, Cancer Research UK, cancer stress responses, cancer-selective therapeutic window, Centre for Cancer Drug Discovery, chemical probes, compound 53, crystal structure, DEAH-box RNA helicases, DHX8, Dr Rob van Montfort, drug resistance, fragment-based drug design, gene expression, hard-to-drug targets, helicase domain, Hit Discovery and Structural Design Group, HSF1, ICR, ICR and Merck KGaA Advance Fragment-Based Approach to Target DHX8, Journal of Medicinal Chemistry, lung cancer cells, Medicinal Chemistry, Merck KGaA, mRNA splicing, nanomolar concentrations, New Small-Molecule Inhibitors Open Route to Underexplored RNA Helicase Cancer Targets, oncogenes, pathfinder molecules, Pathfinder Molecules Show Potential to Unlock New Family of Cancer Drug Targets, pre-mRNA splicing, protein translation, RNA binding, RNA helicase family, RNA processing, RNA-competitive inhibitors, small molecule inhibitors, spliceosome, structural biology, structure-guided medicinal chemistry, target engagement, The Institute of Cancer Research London, therapeutic cancer targets, underexploited drug targets, X-ray crystallography
(IN BRIEF) The Institute of Cancer Research, London, has welcomed the US FDA approval of capivasertib for patients with PTEN-deficient advanced prostate cancer, marking the first regulatory approval of the targeted drug in prostate cancer. Capivasertib blocks AKT, a cancer-driving … Read the full press release
Posted in Business, Education, European Union, Healthcare, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged 3D protein structure, abiraterone, advanced cancer, advanced prostate cancer, AKT inhibitor, AKT pathway, AKT1 mutations, Astex Pharmaceuticals, AstraZeneca, breast cancer, cancer cell growth, cancer cell survival, cancer progression, Cancer Research Technology Limited, Cancer Research UK, CAPItello-281 trial, CAPItello-291 trial, capivasertib, Capivasertib Gains First Prostate Cancer Approval Following Decades of ICR-Led AKT Research, Centre for Cancer Drug Discovery, drug discovery, European Union, FDA, FDA Approval of Capivasertib Marks New Targeted Treatment Option for Advanced Prostate Cancer, fragment-based drug design, fulvestrant, HER2-negative breast cancer, HR-Positive Breast Cancer, ICR, ICR Welcomes FDA Approval of Capivasertib for PTEN-Deficient Advanced Prostate Cancer, ICR Welcomes Milestone FDA Decision for Targeted Therapy in PTEN-Deficient Prostate Cancer, Nature Communications, Nice, oncology research, overall survival, Phase III Trial, PI3 kinase pathway, PIK3CA mutations, precision oncology, Professor Kristian Helin, Professor Paul Workman, prostate cancer patients, prostate cancer treatment, PTEN-deficient prostate cancer, PTEN-deficient tumours, regulatory approval, small molecule inhibitors, targeted therapy, The Institute of Cancer Research, United Kingdom
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?